Blog - Page 1186 of 5760

ThursdayDec 02, 2021 12:38 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, blood pressure findings from HYPER-H21-3 will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4. The study protocols for HYPER-H21-4 are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. HYPER-H21-4, which…

ThursdayDec 02, 2021 12:03 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Switzerland Ethics Committee Approval of Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has received approval from the Switzerland Ethics Committee (swissethics) — the first approval of its kind from a European ethics committee — for its study of Berubicin. Exclusive to CNS Pharmaceuticals, Berubicin is the first anthracycline that appears to cross the blood-brain barrier; the substance is being assessed in a global study designed to evaluate efficacy and safety in the treatment of recurrent glioblastoma multiforme (“GBM”). The adaptive, multicenter, open-label, randomized and controlled study…

ThursdayDec 02, 2021 11:42 am

QualityStocksNewsBreaks – Simply Sonoma Enters Growing CBD-Infused Beverages Space

Simply Sonoma, a company committed to offering CBD products for the environmentally conscious consumer, is branching out into the beverage space with an alcohol-free, CBD wine product as well as a Pinot Noir/CBD sparkling product. A Facts and Factors report expects that the global CBD-infused beverages market will grow at a CAGR of approximately 27.5% between 2021 and 2026, driven by the rising authorization and certification for recreational cannabis in countries such as the United States and Canada (https://ibn.fm/rQu00). Furthermore, there is a growing movement away from smoking cannabis and adopting healthier edible options because of the increasing incidence of…

ThursdayDec 02, 2021 11:31 am

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Plans Opening of Two Additional Ketamine Wellness Centers

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that subsidiary Ketamine Wellness Centers (“KWC”) is planning to open new clinics in Salt Lake City, Utah, and Reno, Nevada; the clinics are slated to open by February 2022. The new clinics will bring the total of KWC locations to 12; the company currently has 10 ketamine infusion treatment clinics in eight different states and is positioned as the largest chain of wellness centers in the country. The Utah location will be one of KWC’s largest clinics, and the Reno clinic is strategically…

ThursdayDec 02, 2021 10:28 am

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Receives Initial Orders from Mexico, Spain

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is expanding internationally. The company’s Flora Beauty division received its first-ever orders for its Mind Naturals and Awe CBD skincare brands for the Spanish and Mexican markets; the company plans to ship the product this month. Flora Beauty’s Mind Naturals brand is designed with young consumers who are just starting a skincare routine while its the AWE brand targets consumers who value customized and personal experiences. The Mind Naturals line was recently named a top-12 finalist in a global pitch competition sponsored by Glosswire. The…

ThursdayDec 02, 2021 10:01 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its receipt of confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Tryp’s Investigational New Drug (“IND”) application is complete and that the company may proceed with its clinical study in fibromyalgia. The trial, which the company expects to initiate in 2022, is being conducted with Kevin Boehnke, Ph.D. from the University of Michigan and will evaluate Tryp’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. “The upcoming phase 2a study with…

ThursdayDec 02, 2021 9:30 am

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Expands POC Health Lab Testing to Include Kidney Function Marker

Avricore Health is a point of care pharmacy services developer that is providing lab-quality testing for select health conditions at pharmacies in Canada Avricore’s trademarked HealthTab(TM) platform networks patients, pharmaceutical professionals and other medical providers with a patient-privacy respecting solution that helps patients monitor their conditions at local community stores without the necessity of busy doctors’ offices scheduling In addition to the kidney-function monitoring solution announced just recently, HealthTab is currently outfitted to provide lab results for evaluating diabetes, heart disease, COVID, RSV, and other viral exposures Avricore’s pilot HealthTab rollout includes sites in eastern Canada’s Ontario province and western…

ThursdayDec 02, 2021 9:30 am

Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited

NMRD releases fiscal Q2-2021 results, provides business update Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory board Company operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently released its fiscal Q2-2021 results and provided a business update (https://ibn.fm/TX286). Financial highlights from the announcement included $26.8M cash on hand, and receipt of…

ThursdayDec 02, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Touts Highlights of ‘Transformative’ Second-Quarter Performance

Report notes significant and swift advancements in company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment benefits that address limitations of oral psilocybin CYBN programs and new psychedelic chemical entities have potential to transform treatment landscape for various psychiatric and neurological conditions Q2 2021 has been a transformative quarter for Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM). The company released its financial and operational report for the period recently, with notable company milestones and achievements highlighted (https://ibn.fm/ucAed). “The first half of the year has been a transformative period…

ThursdayDec 02, 2021 9:25 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Future of Healthcare Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting in the upcoming Stifel GMP second annual Future of Healthcare Conference. The conference, which is slated for Dec. 8, 2021, will include a presentation by Cybin CEO Doug Drysdale. According to the announcement, Drysdale’s presentation is scheduled to start at 3:30 p.m. ET. Following the presentation, interested viewers can view an archived version of the webcast on Cybin’s investor relations website. Cybin is working to create safe and effective therapeutics for patients to address a multitude of mental health issues. To view the…

Site Search

Company Search

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Switzerland Ethics Committee Approval of Pivotal Berubicin Study

QualityStocksNewsBreaks – Simply Sonoma Enters Growing CBD-Infused Beverages Space

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Plans Opening of Two Additional Ketamine Wellness Centers

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Receives Initial Orders from Mexico, Spain

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Expands POC Health Lab Testing to Include Kidney Function Marker

Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Touts Highlights of ‘Transformative’ Second-Quarter Performance

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Future of Healthcare Conference

Market Basics

Newsletter Publishers

Public Companies